Asieris announces NMPA has accepted the New Drug Application for APL-1706, an Imaging Drug for Diagnosing and Management of Bladder Cancer
November 29, 2023 Asieris announces NMPA has accepted the New Drug Application for APL-1706, an Imaging Drug for Diagnosing and Management of Bladder Cancer
October 16, 2023 Asieris’First Product Dipaite Achieves Commercialization and Launches in China, First Prescription Issued in Shanghai
October 12, 2023 Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress
October 6, 2023 Asieris to Unveil First-ever Results of the Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the 2023 SIU Annual Meeting
September 20, 2023 The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
September 14, 2023 Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC